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Abstract
Objective: Women with congenital heart disease (CHD) are at increased risk of pregnancy 
complications and need information on safe, effective contraceptive methods to avoid unintended 
pregnancy. This systematic review examines evidence regarding safety of contraceptive use among 
women with CHD.
Methods: The PubMed database was searched for any peer-reviewed articles published through 
April 2018 that included safety outcomes associated with reversible contraceptive methods among 
women with CHD.
Results: Five articles met inclusion criteria: three studies comparing contraceptive users to 
nonusers and two noncomparative studies. Sample sizes ranged from 65 to 505 women with CHD. 
Two studies found a higher percent of thromboembolic complications among women with Fontan 
palliation or transposition of the great arteries using oral contraceptives. One study, among women 
with Fontan palliation, found no increased risk of thromboembolic complications between 
contraceptive users (not separated by type) and nonusers. Two studies found no endocarditis 
among intrauterine device users.
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Conclusions: There is a paucity of data regarding the safety of contraceptive methods among 
women with CHD. Limited evidence suggests an increased incidence of thromboembolic 
complications with use of oral contraceptives. Further studies are needed to evaluate contraceptive 
safety and quantify risk in this growing population. There is also limited data regarding the safety 
of contraceptive methods among women with CHD. Further information is needed to assist 
practitioners counseling women with CHD on safety of contraceptive methods.
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1 | INTRODUCTION
The population of women of child bearing age (18–44 years) in the United States living with 
congenital heart disease (CHD) was estimated at 340 000 in 2010 and continues to grow.1 
Survival of individuals with CHD in all age groups has improved dramatically with advances 
in medical and surgical treatment. With enhanced survival, there is an increasing need to 
consider reproductive health concerns for women with CHD. Pregnancy among women with 
CHD confers an increased risk of maternal and infant morbidity and mortality.2 The 
incidence of unintended pregnancy in women with CHD is as high as 54%, compared to 
45% in the general population, and a large proportion of women with CHD report using less 
effective methods (eg, barrier, withdrawal, and fertility awareness-based) which are 
associated with failure rates of ≥18 per 100 women per year, or no contraception.3–5 
Therefore, it is important that women with CHD receive appropriate counseling regarding 
the safety and failure rates of contraception methods and the risks of unintended pregnancy.
Women with CHD are at elevated risk of certain adverse events relative to the general 
population and some contraceptive methods could further increase that risk to an 
unacceptable level or interact with disease progression. Potential risks associated with 
contraceptive use vary, depending on the type of contraceptive method and the severity of 
the CHD. For women with CHD, theoretical safety concerns with use of some hormonal 
contraceptive methods (particularly combined hormonal contraceptives, which contain 
estrogen plus progestin) include increased risk of arterial and venous thrombosis, fluid 
retention, and interactions with cardiovascular medications.6–10 Theoretical concerns with 
use of intrauterine devices (lUDs) include arrhythmia, vagal response, and infection leading 
to endocarditis, more likely at the time of insertion.11–13 However, little direct information 
exists on the safety of contraceptive methods for women with CHD. Therefore, we 
conducted this systematic review to assess whether, among women with CHD, adverse 
outcomes differed between women who used and did not use contraception, by type of 
method.
2 | METHODS
This review was conducted in accordance with the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses guidelines.14
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2.1 | Literature search
The authors searched the PubMed database for all relevant peer-reviewed articles in any 
language published from database inception through April 2018. The search strategy 
included terms for CHD, including patent foramen ovale (PFO), lUDs, and hormonal 
contraceptives (Appendix 1). A search of scientific conference abstracts or unpublished 
literature was not performed.
2.2 | Study selection
The key question of interest was whether, among women with CHD, adverse outcomes 
differed between women who used and did not use contraception. Articles examining the 
association between contraception safety and women with acquired cardiac disease, 
including ischemic heart disease, cardiomyopathy, or peri-partum cardiomyopathy, were 
excluded when the article did not report outcomes separately among women with CHD.15,16 
Articles which only examined women with valvular heart disease were also excluded.
Articles were included in which women were using the following reversible contraceptive 
methods: copper lUDs, levonorgestrel IUDs, progestin-only implants, progestin-only 
injectables (including depot medroxyprogesterone acetate [DMPA] and norethisterone 
enanthate), progestin-only pills, combined oral contraceptives, combined hormonal patch, or 
combined vaginal ring. Articles reporting outcomes among women with CHD who 
underwent sterilization were excluded, as the potential risks of sterilization are often related 
to surgery and anesthesia rather than the contraceptive method. Barrier and other methods 
(eg, fertility awareness-based methods) were not included as their safety is not expected to 
be affected by CHD. Outcomes of interest included potential complications related to 
hormonal exposure (eg, thromboembolism or fluid retention) or IUD insertion (eg, infection, 
arrhythmia, or vagal responses).
To answer the key study question, study designs of interest included comparative studies (eg, 
randomized controlled trials, cohort, or case-control studies) examining adverse events 
among women with CHD using and not using contraception. However, noncomparative 
studies that reported adverse outcomes in the population of interest were also included, 
given the limited number of comparative studies published on contraceptive safety in women 
in CHD. Studies evaluating contraceptive use and risk of subsequent pregnancy with a fetus 
with CHD were excluded, as were review articles and case reports. Articles in languages 
other than English were translated if, on initial review, the article seemed to meet inclusion 
criteria. Titles and abstracts were reviewed independently by two coauthors (GA and SLF) to 
assess whether the articles met the inclusion criteria. Full articles were then reviewed by all 
authors to confirm inclusion. At each step, the authors discussed any disagreements and 
came to a decision on the article’s inclusion.
2.3 | Study quality assessment and data synthesis
lnformation from each article was abstracted independently by two coauthors (GA and SLF) 
and confirmed by the third author (NT). The quality of each study was assessed using the 
United States Prevention Services Task Force (USPSTF) grading system.17 Based on the 
USPSTF criteria, authors graded each study’s research design (“I” for properly randomized 
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controlled trials, “11–1” for controlled trials without randomization, “II-2” for cohort or 
case-control studies, and “II-3” for multiple time series with or without intervention) and its 
internal validity (“good,” “fair,” or “poor”). Several factors were considered which might 
impact study quality and potential biases, such as whether the study had clear descriptions of 
types of CHD and contraceptive methods and whether outcomes were self-reported or 
confirmed by physician or medical record review. Summary measures were not calculated 
due to heterogeneity in disease, contraceptive methods, and outcomes reported.
3 | RESULTS
The search strategy identified 271 articles (Figure 1). After reviewing titles and abstracts, 43 
full-length articles were reviewed and 5 met the inclusion criteria (Table 1).4,18–21 We 
excluded 38 articles because they did not include the population of interest, were review 
articles, or did not address the question of interest. We found no additional articles after 
reviewing references and review articles. There were three cohort studies,4,19,20 with data 
available to compare contraceptive users to nonusers, and two noncomparative studies18,21 
reporting complications among contraceptive users without a comparison group of nonusers. 
The studies included women using a variety of reversible contraceptive methods.
A retrospective cohort study, conducted from 2011 to 2014, reported on 505 women with a 
variety of types of CHD attending 9 adult CHD clinics in North America.20 Overall, 4% of 
women experienced a thromboembolic event while using oral contraceptives, with a higher 
percentage among women with complex CHD (9%) than among women with less complex 
CHD (1%, P value for comparison .003). Among 31 women with Fontan physiology, 39% of 
women who had ever used oral contraceptives and 28% of current oral contraceptive users 
experienced a thromboembolic event (all in women using combined oral contraceptives), 
while 17% of never-users experienced an event. Among 38 women with D-transposition of 
the great arteries, 13% of current users (combined and progestin-only pills) experienced a 
thromboembolic event, compared with no women in the never-user group.
A retrospective cohort study conducted in the United States using data from 1973 to 2012 
reported on 138 women with Fontan palliation and available contraceptive information.4 
Among these women, 12% (17) were using combined hormonal contraceptives, barrier 
methods, or sterilization (not further differentiated), 8% (11) were using DMPA, 7% (10) 
were using lUDs (type not specified), and 1% (2) were using progestin-only pills.
Reported thromboembolic complications were similar between women using any type of 
contraception compared to women using no contraception (8% vs 11%, P = .46). Of these 
events, pulmonary emboli (PE) occurred in 17 women using combined oral contraceptives; 
however, the authors did not report which contraceptive methods were used by the remaining 
women who experienced thromboembolism. There were no reports of complications, 
including endocarditis, among women using lUDs. Authors did not report year of 
contraceptive use or timing relative to thromboembolism occurrence.
A retrospective cohort study conducted in Germany (years of data collection not reported, 
published 2011) reported on 65 women with a PFO (diagnosed by echocardiography) and 
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history of cryptogenic stroke.19 The women were evaluated for silent PE using ventilation 
perfusion scintigraphy. Nine of the 65 women reported taking oral contraceptives (type not 
reported). Silent PE was found in 6 of 9 oral contraceptive users (67%) and 19 of 56 
nonusers (34%); these percentages were not reported by the authors but were hand-
calculated from published data for the purpose of this review and direct statistical 
comparison was not reported.
A noncomparative study was conducted in Spain from 2007 to 2010 of 237 women with 
CHD (92% biventricular CHD, 66% New York Heart Association Heart functional class I) 
referred for preconception counseling at a CHD clinic.18 This study had a retrospective and 
prospective component. The retrospective component included data abstracted from medical 
records. Of 79 women who reported previous use of combined hormonal contraceptives 
(combined oral contraceptives and patch), 3 (3.8%) reported a thromboembolic event while 
using the combined hormonal contraceptive. Among 145 women who inquired about 
contraception in the CHD clinic, 107 began desogestrel progestin-only pills. At 
approximately 1 year of follow-up, 63 were continuing to use progestin-only pills, 16 were 
using implants or progestin lUDs, and the remainder were using barrier or no methods. No 
cardiac or thrombotic events were reported among the 107 women initially started on the 
desogestrel progestin-only pill.
A retrospective noncomparative study conducted in Italy from 1980 to 1990 reported on 108 
women with CHD (53 with cyanotic disease of which 8 had Eisenmenger syndrome, 23 with 
left-right shunt, and the remainder with outflow tract obstruction).21 Over half had 
undergone cardiac surgery, 70% of which were considered “radical corrective surgeries,” 
which was not further defined. Review of medical records during a 10-year period identified 
13 women using oral contraceptives (type reported for 1 woman only) and 18 women using 
lUDs (type not reported). One woman with atrial septal defect developed pulmonary 
hypertension (confirmed with cardiac catheterization) while using combined oral 
contraceptives. No women using oral contraceptives developed hypertension or 
thromboembolic disease. One woman with unspecified CHD developed a local infection 
(not further defined) while using an IUD. No endocarditis occurred in lUD users.
4 | DISCUSSION
4.1 | Summary
Five studies, two from North America and three from Europe, provide limited information 
on complications among women with CHD using contraception. Two of three comparative 
studies found a higher percent of thromboembolic complications among women with Fontan 
palliation or transposition of the great arteries using oral contraceptives than among women 
not using oral contraceptives; however, statistical testing was not reported for these 
comparisons.19,20 One of these studies found a higher percent of thromboembolic conditions 
in women with more severe CHD compared with mild CHD.20 In contrast, one study of 
women with Fontan palliation found no increased risk of thromboembolic complications 
among women using contraception (not separated) compared with nonusers.4 Two studies 
found no endocarditis among IUD users.4,21
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This body of evidence is extremely limited. All studies were rated as poor quality. Studies 
had small numbers of women with CHD or using contraception. Two studies did not have a 
comparison group of nonusers18,21 and two others did not report statistical comparisons 
between users and nonusers.19,20 Two studies did not report outcomes by specific type of 
contraception, but rather grouped all methods together.4,19 In three studies, the temporal 
sequence of contraceptive use and the adverse event was unclear.18–20
4.2 | Potential risks
Given the lack of high-quality direct evidence regarding safety of contraceptives among 
women with CHD, it is important to consider whether there are any theoretical health 
concerns with use of contraception, beyond that of the general population. Contraceptive use 
could further increase risks of certain adverse events in women with CHD to an 
unacceptable level or could interact with CHD disease process or treatment to introduce new 
risks. Concerns will vary by type of CHD and contraceptive method, but may include an 
increased risk of thrombosis, endocarditis after IUD insertion, heart failure, and arrhythmias, 
beyond that of the general population of contraceptive users, as well as cardiac-related drug 
interactions.
Women with certain cardiac conditions are at elevated risk for venous and arterial 
thrombosis, including women with pulmonary artery hypertension, Fontan repair, atrial 
fibrillation, mechanical heart valves, and significant ventricular dysfunction.6,22 It is well 
established that combined oral contraceptive use by women in the general population 
increases the risk of venous and arterial thrombosis compared with nonuse, by 
approximately threefold for venous thromboembolism (VTE), twofold for ischemic stroke, 
and 1.6-fold for myocardial infarction (MI).7,23 The risk of arterial thrombosis is also 
increased among women with hypertension who use combined oral contraceptives.24 These 
effects are largely due to impacts of estrogen on the clotting system but may also be 
impacted by different progestin types.25 Studies have generally not demonstrated an elevated 
risk of venous or arterial thrombosis with use of progestin-only contraceptives by women in 
the general population compared with nonuse.26 A few studies have found an elevated risk 
of VTE with DMPA; however, there is no evidence examining these associations among 
women with thrombosis risk factors.26 It is unknown whether estrogen affects the 
mechanisms that lead to thrombosis among women with CHD, but combined hormonal 
contraceptives might further increase the risk of thrombosis in these women.
Certain CHD are associated with endocarditis, including CHD repaired with prosthetic 
cardiac valves and prior history of infective endocarditis.12 Theoretically, initiation of an 
IUD in these individuals could lead to disseminated infection and endocarditis through 
bacterial seeding and spread. However, the incidence of pelvic infection among women 
initiating IUDs is very low and antibiotic prophylaxis does not impact risk of pelvic 
inflammatory disease.13,27 Additionally, antibiotic prophylaxis is not recommended prior to 
genitourinary procedures, given no evidence of an association between genitourinary 
procedures and endocarditis.28
Heart failure secondary to ventricular dysfunction can be a serious sequela of CHD. Fluid 
retention, if exacerbated by hormonal contraceptives, could initiate or worsen heart failure. 
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However, studies have shown mixed results on blood pressure and fluid effects in women 
exposed to contraceptive or noncontraceptive doses of hormones.29–32 Overall, effects on 
fluid balance related to hormonal contraceptives are likely of minimal clinical significance.
Some women with CHD are at risk for arrhythmias, including women with Fontan 
palliation, atrial dilation or cardiac dysfunction.11 While there is no evidence demonstrating 
an increased incidence of adverse events with IUD insertion in women with CHD, some 
studies have reported arrhythmia in healthy women during and following IUD insertion or 
while using hormonal contraceptives. However, these instances are likely uncommon and the 
clinical significance is unknown. A small percentage of women experience vasovagal 
responses during IUD insertion. Estimates report less than 2% incidence of syncope and a 
range of 2%−30% incidence of bradycardia, with higher incidences found during insertion 
of older large and rigid IUDs.33,34 These symptoms may be worsened in the setting of 
pulmonary artery hypertension or Fontan palliation.6,35
Women with CHD may use teratogenic medications, such as certain antihypertensives, 
underscoring the need for effective contraception. However, some cardiac medications, such 
as bosentan and warfarin, may interact with hormonal contraceptives, thereby potentially 
decreasing effectiveness of either drug. Bosentan used in the treatment of pulmonary artery 
hypertension induces CYP3A4 activity and could decrease concentrations of contraceptive 
hormones8,9; however, impact on contraceptive effectiveness is unknown. Warfarin may 
interact with hormonal contraceptives, leading to either decreased or increased warfarin 
requirements, although this information is limited to pharmacokinetic studies, case reports 
and case series and clinical implications are unclear.10,36
When considering the risk/benefit ratio for contraception use in women with CHD, it is 
important to factor the risk of pregnancy. Potential complications of contraception may be 
outweighed by the significant morbidity and mortality faced by women with certain CHD 
who become pregnant, such as those with pulmonary artery hypertension.37 Highly effective 
contraception, such as lUDs, implants, or sterilization, are associated with pregnancy rates of 
less than 1 per 100 users and may be preferable for women with these diseases who wish to 
avoid pregnancy. However, surgical risk should be considered in women who desire 
sterilization. In addition, some women with CHD may benefit from noncontraceptive uses of 
some methods of contraception, such as reduced bleeding among women with abnormal 
uterine bleeding using anticoagulants.38
4.3 | Published recommendations
The safety of different contraceptives likely varies widely among women with CHD, given 
the range of severity of CHD. Despite this heterogeneity, the American College of 
Cardiology/American Heart Association,11 the Royal College of Obstetricians and 
Gynecologists,12 the European Society of Cardiology39 and expert groups from Canada6 and 
the United Kingdom37 have published recommendations for use of contraception among 
women with CHD based on expert opinion. One published recommendation suggests that 
women with simple CHD lesions are likely at no increased risk compared with the general 
population.6 However, all recommend that women with CHD at high risk for thrombosis 
avoid combined hormonal contraceptives.6,11,12,37 Some recommend avoidance or caution 
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and careful monitoring of IUD insertion in women for whom a vagal response would be 
poorly tolerated.6,12,37 Two also recommend caution with use of progestin-only 
contraceptives among patients with heart failure due to concern for fluid retention.6,11 Two 
acknowledge uncertainty regarding risk of endocarditis with IUD insertion and recommend 
individualized management.11,12 The US Medical Eligibility Criteria for Contraceptive Use 
includes recommendations for safe use of contraception among women with certain 
comorbid or analogous medical conditions (eg, hypertension, ischemic heart disease, peri-
partum cardiomyopathy, and deep venous thrombosis/pulmonary embolism), which might 
be considered when counseling women with CHD.40
4.4 | Conclusions
In conclusion, this review identified limited Level II-2 to II-3 poor-quality evidence on 
contraceptive safety in women with CHD. Several published guidelines and expert reviews 
provide information on theoretical risks of contraceptive methods in women with specific 
types of CHD. Collaboration and communication between a woman’s cardiologist and 
contraceptive provider may be helpful in providing comprehensive counseling about 
potential risks and benefits of all contraceptive methods compared to risk of unintended 
pregnancy. Future studies evaluating contraceptive safety among women with CHD would 
help quantify the risks, beyond that of the general population.
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APPENDIX 1
Search strategy for congenital heart disease or patent foramen ovale and 
reversible contraceptives
((((((((((((((“Contraceptives, Oral, Combined”[Mesh] OR “Contraceptives, Oral”[Mesh] OR 
“Contraceptives, Oral, hormonal”[Mesh] OR “Contraceptives, Oral, Combined”
[Pharmacological Action]) OR (contracept* AND (oral OR pill OR tablet)) OR ((combined 
hormonal) OR (combined oral) AND contracept*) OR (contracept* AND (ring OR patch)) 
OR “ortho evra” OR NuvaRing) OR (progestin* OR progestins[MeSH] OR 
Progesterone[MeSH] OR progesterone OR progestogen* OR progestagen* OR 
“Levonorgestrel”[Mesh] OR Levonorgestrel OR “Norgestrel”[Mesh] OR norgestrel OR 
etonogestrel AND contracept*) OR dmpa OR “depo medroxyprogesterone” OR “depo 
provera” OR “net en” OR “norethisterone enanthate” OR “norethindrone enanthate” OR 
(contracept* AND (inject* OR implant)) OR ((levonorgestrel OR etonogestrel) AND 
implant) OR implanon OR nex- planon OR jadelle OR norplant OR uniplant OR sino-
implant OR (levonorgestrel-releasing two-rod implant) OR (“Intrauterine Devices, 
Medicated”[Mesh] OR ((intrauterine OR intra-uterine) AND (device OR system OR 
contracept*)) OR IUD OR IUCD OR IUS OR mirena OR Skyla OR paragard OR “Copper 
T380” OR CuT380 OR “Copper T380a” OR “Cu T380a”))) AND Humans[Mesh])) AND 
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((((((((((((“heart defects, congenital”[MeSH Terms] OR (“heart”[All Fields] AND “defects”
[All Fields] AND “congenital”[All Fields]) OR “congenital heart defects”[All Fields] OR 
(“heart”[All Fields] AND “defects”[All Fields] AND “congenital”[All Fields]) OR “heart 
defects, congenital”[All Fields]))) OR ((“congenital”[All Fields] AND “heart”[All Fields] 
AND “disease”[All Fields]) OR “congenital heart disease”[All Fields]))) OR ((“pediatric”
[All Fields] AND “cardiology”[All Fields]) OR “pediatric cardiology”[All Fields])))) AND 
Humans[Mesh])) OR ((((“heart septal defects, atrial”[MeSH Terms] OR (“heart” AND 
“septal” AND “defects” AND “atrial”) OR “atrial heart septal defects” OR (“atrial” AND 
“septal” AND “defect”) OR “atrial septal defect”)) AND (“foramen ovale, patent”[MeSH 
Terms] OR (“foramen” AND “ovale” AND “patent”) OR “patent foramen ovale” OR 
(“patent” AND “foramen” AND “ovale”)))))) AND Humans[Mesh]))).
REFERENCES
1. Gilboa SM, Devine OJ, Kucik JE, et al. Congenital heart defects in the United States: estimating the 
magnitude of the affected population in 2010. Circulation. 2016;134:101–109. [PubMed: 27382105] 
2. Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Outcome of pregnancy in women with congenital 
heart disease: a literature review. J Am Coll Cardiol. 2007;49:2303–2311. [PubMed: 17572244] 
3. Lindley KJ, Madden T, Cahill AG, Ludbrook PA, Billadello JJ. Contraceptive use and unintended 
pregnancy in women with congenital heart disease. Obstet Gynecol. 2015;126:363–369. [PubMed: 
26241427] 
4. Pundi KN, Pundi K, Johnson JN, et al. Contraception practices and pregnancy outcome in patients 
after Fontan operation. Congenit Heart Dis. 2015;11:63–70. [PubMed: 26239864] 
5. Finer LB, Zolna MR. Declines in unintended pregnancy in the United States, 2008–2011. N Engl J 
Med. 2016;374:843–852. [PubMed: 26962904] 
6. Silversides CK, Sermer M, Siu SC. Choosing the best contraceptive method for the adult with 
congenital heart disease. Curr Cardiol Rep. 2009;11:298–305. [PubMed: 19563730] 
7. Peragallo Urrutia R, Coeytaux RR, McBroom AJ, et al. Risk of acute thromboembolic events with 
oral contraceptive use: a systematic review and meta-analysis. Obstet Gynecol. 2013;122:380–389. 
[PubMed: 23969809] 
8. Srinivas NR. Clinical drug-drug interactions of bosentan, a potent endothelial receptor antagonist, 
with various drugs: physiological role of enzymes and transporters. Gen Physiol Biophys. 
2016;35:243–258. [PubMed: 27045668] 
9. van Giersbergen PL, Halabi A, Dingemanse J. Pharmacokinetic interaction between bosentan and 
the oral contraceptives norethisterone and ethinyl estradiol. Int J Clin Pharmacol Ther. 
2006;44:113–118. [PubMed: 16550733] 
10. Zingone MM, Guirguis AB, Airee A, Cobb D. Probable drug interaction between warfarin and 
hormonal contraceptives. Ann Pharmacother. 2009;43:2096–2102. [PubMed: 19934391] 
11. Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 guidelines for the management of 
adults with congenital heart disease: a report of the American College of Cardiology/American 
Heart Association Task Force on practice guidelines (writing committee to develop guidelines on 
the management of adults with congenital heart disease). Circulation. 2008;118:e714–e833. 
[PubMed: 18997169] 
12. Contraceptive Choices for Women with Cardiac Disease. 2014 https://www.fsrh.org/standards-and-
guidance/documents/ceu-guidance-contraceptive-choices-for-women-with-cardiac/. Accessed 
March 6, 2018.
13. Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic 
inflammatory disease: an international perspective. Lancet. 1992;339:785–788. [PubMed: 
1347812] 
14. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic 
reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
Abarbanell et al. Page 9
Congenit Heart Dis. Author manuscript; available in PMC 2020 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
15. Avila WS, Grinberg M, Melo NR, Aristodemo Pinotti J, Pileggi F. Contraceptive use in women 
with heart disease. Arq Bras Cardiol. 1996;66:205–211. [PubMed: 8935685] 
16. Suri V, Aggarwal N, Kaur R, Chaudhary N, Ray P, Grover A. Safety of intrauterine contraceptive 
device (copper T 200 B) in women with cardiac disease. Contraception. 2008;78:315–318. 
[PubMed: 18847580] 
17. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: 
a review of the process. Am J Prev Med. 2001;20:21–35.
18. Pijuan-Domenech A, Baro-Marine F, Rojas-Torrijos M, et al. Usefulness of progesterone-only 
components for contraception in patients with congenital heart disease. Am J Cardiol. 
2013;112:590–593. [PubMed: 23706389] 
19. Tanislav C, Puille M, Pabst W, et al. High frequency of silent pulmonary embolism in patients with 
cryptogenic stroke and patent foramen ovale. Stroke 2011;42:822–824. [PubMed: 21257827] 
20. Miner PD, Canobbio MM, Pearson DD, et al. Contraceptive practices of women with complex 
congenital heart disease. Am J Cardiol. 2017;119:911–915. [PubMed: 28087052] 
21. Rabajoli F, Aruta E, Presbitero P, Todros T. Risks of contraception and pregnancy in patients with 
congenital cardiopathies. Retrospective study on 108 patients. G Ital Cardiol. 1992;22:1133–1137. 
[PubMed: 1291407] 
22. Lindley KJ, Conner SN, Cahill AG, Madden T. Contraception and pregnancy planning in women 
with congenital heart disease. Curr Treat Options Cardiovasc Med. 2015;17:50. [PubMed: 
26403241] 
23. Roach RE, Helmerhorst FM, Lijfering WM, Stijnen T, Algra A, Dekkers OM. Combined oral 
contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst Rev. 
2015;CD011054.
24. Curtis KM, Mohllajee AP, Martins SL, Peterson HB. Combined oral contraceptive use among 
women with hypertension: a systematic review. Contraception. 2006;73:179–188. [PubMed: 
16413848] 
25. Tchaikovski SN, Rosing J. Mechanisms of estrogen-induced venous thromboembolism. Thromb 
Res. 2010;126:5–11. [PubMed: 20163835] 
26. Tepper NK, Whiteman MK, Marchbanks PA, James AH, Curtis KM. Progestin-only contraception 
and thromboembolism: a systematic review. Contraception. 2016;94:678–700. [PubMed: 
27153743] 
27. Grimes DA, Schulz KF. Antibiotic prophylaxis for intrauterine contraceptive device insertion. 
Cochrane Database Syst Rev. 2001:CD001327.
28. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the 
American Heart Association: a guideline from the American Heart Association Rheumatic Fever, 
Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, 
and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and 
the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 
2007;116:1736–1754. [PubMed: 17446442] 
29. Stachenfeld NS. Sex hormone effects on body fluid regulation. Exerc Sport Sci Rev. 2008;36:152–
159. [PubMed: 18580296] 
30. de Nadai MN, Nobre F, Ferriani RA, Vieira CS. Effects of two contraceptives containing 
drospirenone on blood pressure in normotensive women: a randomized-controlled trial. Blood 
Press Monit. 2015;20:310–315. [PubMed: 26154851] 
31. Kharbanda EO, Parker ED, Sinaiko AR, et al. Initiation of oral contraceptives and changes in blood 
pressure and body mass index in healthy adolescents. J Pediatr. 2014;165:1029–1033. [PubMed: 
25189822] 
32. Roos-Hesselink JW, Cornette J, Sliwa K, Pieper PG, Veldtman GR, Johnson MR. Contraception 
and cardiovascular disease. Eur Heart J. 2015;36:1728–1734, 34a-34b. [PubMed: 25926560] 
33. Hall AM, Kutler BA. Intrauterine contraception in nulliparous women: a prospective survey. J Fam 
Plann Reprod Health Care. 2016;42:36–42. [PubMed: 25854550] 
34. Farmer M, Webb A. Intrauterine device insertion-related complications: can they be predicted? J 
Fam Plann Reprod Health Care. 2003;29:227–231. [PubMed: 14662057] 
Abarbanell et al. Page 10
Congenit Heart Dis. Author manuscript; available in PMC 2020 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
35. Olsson KM, Jais X. Birth control and pregnancy management in pulmonary hypertension. Semin 
Respir Crit Care Med. 2013;34:681–688. [PubMed: 24037634] 
36. Culwell KR, Curtis KM. Use of contraceptive methods by women with current venous thrombosis 
on anticoagulant therapy: a systematic review. Contraception. 2009;80:337–345. [PubMed: 
19751856] 
37. Thorne S, Nelson-Piercy C, MacGregor A, et al. Pregnancy and contraception in heart disease and 
pulmonary arterial hypertension. J Fam Plann Reprod Health Care. 2006;32:75–81. [PubMed: 
16824295] 
38. Maas AH, Euler M, Bongers MY, et al. Practice points in gynecardiology: abnormal uterine 
bleeding in premenopausal women taking oral anticoagulant or antiplatelet therapy. Maturitas. 
2015;82:355–359. [PubMed: 26358933] 
39. Baumgartner H, Bonhoeffer P, De Groot NM, et al. ESC guidelines for the management of grown-
up congenital heart disease (new version 2010). Eur Heart J. 2010;31:2915–2957. [PubMed: 
20801927] 
40. Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. medical eligibility criteria for contraceptive use, 
2016. MMWR Recomm Rep. 2016;65:1–103.
Abarbanell et al. Page 11
Congenit Heart Dis. Author manuscript; available in PMC 2020 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
FIGURE 1. 
Flowchart for inclusion of articles in systematic review
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